Kingsview Wealth Management’s Akebia Therapeutics AKBA Stock Holding History

Kingsview Wealth Management’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-10,959	Closed	-$32K	–	952
2021 Q3	$32K	Sell	10,959 -3,445	-24%	-$9.84K	﹤0.01%	832
2021 Q2	$56K	Sell	14,404 -1,259	-8%	-$4.24K	﹤0.01%	850
2021 Q1	$52K	Sell	15,663 -349	-2%	-$1.26K	﹤0.01%	798
2020 Q4	$45K	Buy	16,012 +3,100	+24%	+$9.05K	﹤0.01%	686
2020 Q3	$32K	Buy	12,912 +2,700	+26%	+$23.7K	﹤0.01%	599
2020 Q2	$139K	Buy	+10,212	New	+$106K	0.01%	550
2019 Q3	–	Sell	-10,877	Closed	-$53K	–	442
2019 Q2	$53K	Sell	10,877 -187	-2%	-$1.06K	0.01%	405
2019 Q1	$91K	Buy	+11,064	New	+$75.9K	0.01%	437

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Kingsview Wealth Management's AKBA Position: Q4 2021 in Review

Kingsview Wealth Management sold out of Akebia Therapeutics (AKBA) in Q4 2021, closing a stake of 10,959 shares — an estimated $32K sold.

Kingsview Wealth Management first reported a position in AKBA in Q1 2019 and held it in 8 quarters. The position peaked at $139K in Q2 2020. 133 funds tracked by Wall St. Rank hold AKBA as of Q4 2021.

Kingsview Wealth Management reported no remaining Akebia Therapeutics position as of Q4 2021 after selling out during the quarter.
Kingsview Wealth Management sold 10,959 Akebia Therapeutics shares in Q4 2021, an estimated $32K.
Kingsview Wealth Management first reported a position in Akebia Therapeutics in Q1 2019 and held it in 8 quarters.
Kingsview Wealth Management's Akebia Therapeutics position peaked at $139K in Q2 2020.
133 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2021.

Based on Kingsview Wealth Management's 13F filing for Q4 2021, filed 17 Feb 2022.